Re: Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial

Samir S. Taneja

    Research output: Contribution to journalComment/debate

    Original languageEnglish (US)
    Pages (from-to)656-658
    Number of pages3
    JournalJournal of Urology
    Volume191
    Issue number3
    DOIs
    StatePublished - 2014

    ASJC Scopus subject areas

    • Urology

    Cite this